Does NEMO bring us a step closer in the fight against melano...

The HNSCC immunotherapy race is on - and it's going to be cl...

While improper to compare life saving treatments to buses - the metaphor when it comes to head and neck squamous cell carcinoma (HNSCC) is clear.

Eye on ASCO Day 3 - Pricey combos cause panic

But is it pharma’s fault?

Further Darzalex results extend hope for PFS in Myeloma

Earlier this year (March), Johnson & Johnson announced that the randomized Phase III CASTOR trial (NCT02136134) achieved its primary endpoint and was stopped early as recommended by the Indepen

Eye on ASCO Day 2 - Precision medicine takes centre stage

Data from one of the largest cancer genomics studies ever conducted.

Positive PIII results for VYXEOS revealed at ASCO

Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun